CVKD
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ
Listed Jan 20, 2023
Healthcare
· Biotechnology
· US
·
cadrenal.com
52w Low $4.21
14.7% of range
52w High $16.50
50d MA $6.24
200d MA $9.53
P/E (TTM)
-1.0x
EV/EBITDA
-0.7x
P/B
4.6x
Debt/Equity
0.0x
ROE
-483.3%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
1.55
50d MA
$6.24
200d MA
$9.53
Avg Volume
49.8K
About
Recent Earnings
Recent Analyst Ratings
Insider Trades
Recent Filings
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
822 A1A North · Ponte Vedra, FL 32082 · US
Date
Time
Est
Rptd
Surp
Base
Gap%
D1%
D2%
D3%
D4%
D5%
Guide ▲★
Mar 31, 2026
AMC
-1.17
-1.41
-20.5%
5.12
+0.4%
-4.3%
-4.1%
-1.1%
-7.1%
+12.3%
—
Nov 10, 2025
AMC
-1.55
-1.31
+15.5%
11.76
+0.9%
+5.0%
-0.9%
-4.8%
-0.3%
+0.8%
—
Aug 11, 2025
AMC
-1.60
-1.87
-16.9%
10.94
+0.5%
-0.3%
+7.1%
+10.6%
-1.9%
+2.9%
—
May 8, 2025
AMC
-1.64
-2.09
-27.4%
15.50
+3.0%
-6.8%
-7.4%
+10.5%
-4.4%
+7.1%
—
Mar 13, 2025
AMC
-1.71
-2.74
-60.2%
17.45
+1.6%
+9.4%
+4.1%
-2.7%
+1.0%
-0.1%
—
Nov 7, 2024
AMC
-1.83
-2.18
-19.1%
16.29
+1.2%
+8.9%
+0.8%
-0.9%
-6.6%
+0.1%
—
Aug 7, 2024
AMC
-19.04
-2.25
+88.2%
6.21
-3.9%
+4.7%
-0.8%
+2.3%
+13.6%
+3.9%
—
May 9, 2024
AMC
-1.05
-1.50
-42.9%
7.28
-1.1%
-5.2%
-4.3%
+0.2%
+0.6%
-3.0%
—
Mar 11, 2024
AMC
-1.35
-0.75
+44.4%
9.76
-4.4%
-10.9%
+1.0%
+1.5%
-1.1%
-4.8%
—
Nov 9, 2023
AMC
-1.05
-1.05
+0.0%
6.60
-3.8%
-4.1%
-2.8%
+2.3%
+16.9%
-7.9%
—
Aug 10, 2023
AMC
—
-1.35
—
11.11
+4.1%
+2.3%
+1.4%
-1.2%
-6.3%
+9.7%
—
May 10, 2023
AMC
—
-0.41
—
22.05
-4.8%
+4.1%
-8.5%
+0.7%
+3.5%
-2.7%
—
Show 2 more
Date
Firm
Action
Grade
Target
Base
Open
Gap%
D1%
D2%
D3%
D4%
D5%
Apr 7
HC Wainwright & Co.
Maintains
Buy → Buy
—
$4.65
$4.50
-3.2%
-7.1%
+12.3%
+2.5%
-4.2%
+4.8%
May 16
HC Wainwright & Co.
Maintains
Buy → Buy
—
$15.14
$15.16
+0.1%
+2.4%
-1.0%
+2.1%
+0.1%
-4.3%
Nov 11
HC Wainwright & Co.
Maintains
Buy → Buy
—
$17.74
$18.00
+1.5%
+0.8%
-0.9%
-6.6%
+0.1%
-5.5%
Jun 6
HC Wainwright & Co.
Maintains
Buy → Buy
—
$7.65
$7.79
+1.8%
-2.0%
-5.9%
-6.2%
+6.3%
-0.6%
May 9
HC Wainwright & Co.
Maintains
Buy → Buy
—
$7.36
$7.20
-2.2%
-1.1%
-5.2%
-4.3%
+0.2%
+0.6%
Mar 14
HC Wainwright & Co.
Maintains
Buy → Buy
—
$8.79
$8.79
+0.0%
+1.5%
-1.1%
-4.8%
+1.8%
+5.3%
No insider trades available.
8-K · 2.02
!! High
Cadrenal Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Cadrenal Therapeutics reported Q1 2026 financial results on May 7, 2026, which investors can review in the accompanying press release for operational performance and cash position details.
May 7
8-K · 8.01
!! High
Cadrenal Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Cadrenal Therapeutics completed its FDA End-of-Phase 2 meeting for CAD-1005, receiving guidance on Phase 3 trial design for this heart inflammation treatment, potentially accelerating development timelines.
Apr 30
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CVKD signed a $2.5 million material agreement, suggesting new revenue opportunities or strategic partnerships that could drive near-term growth and improve financial performance.
Apr 1
8-K
Unknown — 8-K Filing
Cadrenal Therapeutics filed an 8-K with a press release, signaling a material corporate announcement that could impact stock price; investors should review the full press release details to assess the announcement's significance.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Preclinical data supporting CAD-1005's potential efficacy in diabetes and obesity could validate Corvus's therapeutic approach and drive clinical trial advancement, offering significant upside if human trials show similar inflammatory and metabolic improvements.
Mar 12
8-K · 8.01
!! High
Cadrenal Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Cadrenal Therapeutics reports positive trial results for CAD-1005 in heparin-induced thrombocytopenia, potentially establishing a new surrogate endpoint through collaboration with previous sponsor Veralox Therapeutics.
Feb 24
Data updated apr 25, 2026 4:06am
· Source: massive.com
